Karyopharm Therapeutics (NASDAQ:KPTI – Get Free Report) had its price target raised by equities researchers at HC Wainwright from $8.00 to $13.00 in a report released on Wednesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s price target indicates a potential upside of 38.15% from the stock’s previous close.
Other equities analysts also recently issued reports about the company. Rodman & Renshaw raised Karyopharm Therapeutics to a “strong-buy” rating in a research note on Tuesday, March 10th. Piper Sandler reaffirmed an “overweight” rating and issued a $16.00 price objective (up from $8.00) on shares of Karyopharm Therapeutics in a research note on Monday, April 27th. Cantor Fitzgerald began coverage on Karyopharm Therapeutics in a research report on Thursday, February 5th. They set an “overweight” rating for the company. Finally, Robert W. Baird dropped their price target on Karyopharm Therapeutics from $21.00 to $15.00 and set an “outperform” rating for the company in a research report on Wednesday, March 25th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, Karyopharm Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $16.14.
View Our Latest Stock Analysis on KPTI
Karyopharm Therapeutics Price Performance
Karyopharm Therapeutics (NASDAQ:KPTI – Get Free Report) last released its quarterly earnings data on Friday, February 13th. The company reported ($2.23) earnings per share for the quarter, beating the consensus estimate of ($2.26) by $0.03. The firm had revenue of $34.08 million during the quarter, compared to analysts’ expectations of $33.16 million. On average, research analysts expect that Karyopharm Therapeutics will post -4.49 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Karyopharm Therapeutics
Hedge funds have recently made changes to their positions in the business. Jump Financial LLC acquired a new position in Karyopharm Therapeutics in the fourth quarter valued at $396,000. ADAR1 Capital Management LLC boosted its holdings in Karyopharm Therapeutics by 100.0% in the fourth quarter. ADAR1 Capital Management LLC now owns 50,000 shares of the company’s stock valued at $368,000 after acquiring an additional 25,000 shares during the last quarter. Trexquant Investment LP acquired a new position in Karyopharm Therapeutics in the fourth quarter valued at $307,000. Bridgeway Capital Management LLC acquired a new position in Karyopharm Therapeutics in the second quarter valued at $163,000. Finally, Persistent Asset Partners Ltd acquired a new position in Karyopharm Therapeutics in the fourth quarter valued at $135,000. Institutional investors and hedge funds own 66.44% of the company’s stock.
About Karyopharm Therapeutics
Karyopharm Therapeutics (NASDAQ: KPTI) is a clinical-stage biopharmaceutical company focused on discovering and developing novel first-in-class drugs that target the nuclear export protein XPO1. The company’s lead product, selinexor (marketed as XPOVIO), is an oral selective inhibitor of nuclear export (SINE) compound approved for treatment of multiple myeloma and diffuse large B-cell lymphoma. In addition to selinexor, Karyopharm’s pipeline includes second-generation SINE compounds and combination studies in solid tumors and hematologic malignancies.
Founded in 2008 and headquartered in Newton, Massachusetts, Karyopharm has built a research platform around modulation of nuclear export pathways.
Featured Stories
Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
